US Stock MarketDetailed Quotes

RVNC Revance Therapeutics

Watchlist

3.290
-0.280-7.84%

Close Apr 25 16:00 ET

3.370
+0.080+2.43%

Pre 07:29 ET

342.87MMarket Cap-859P/E (TTM)

Revance Therapeutics Stock Forum

Moomoo AI

Mar 1 20:54

Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.

Even After Rising 34% This Past Week, Revance Therapeutics (NASDAQ:RVNC) Shareholders Are Still Down 77% Over the Past Year

Kevin Travers

Jan 8 23:58

ColumnsRevance Therapeutics -14% on Preliminary Q4, FY24 Outlook

$Revance Therapeutics(RVNC.US)$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.

Moomoo AI

Dec 25, 2023 20:26

Concerns raised by insiders' stock selling. CEO Mark Foley's sale was price-wise favorable. Despite no recent insider purchase, the 1.9% insider stake suggests alignment with shareholders.

Possible Bearish Signals With Revance Therapeutics Insiders Disposing Stock

Moomoo AI

Nov 16, 2023 03:07

Despite predictions of Revance Therapeutics outperforming industry revenue growth, anticipated losses for next year have increased, hinting at future challenges. Significant forecast downgrades may amplify market skepticism towards the business.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Analysts Just Cut Their EPS Forecasts Substantially

Moomoo AI

Oct 27, 2023 18:18

Despite strong revenue growth, the company's falling stock suggests pessimism among investors. The firm's consistent losses intensify concerns. Over the long term, Revance Therapeutics' performance could reveal persistent challenges, necessitating careful evaluation prior to investment.

Revance Therapeutics (NASDAQ:RVNC Investor Three-year Losses Grow to 69% as the Stock Sheds US$67m This Past Week

Moomoo AI

Oct 22, 2023 16:23

Revance Therapeutics' healthy balance sheet might be at risk due to its substantial liabilities and EBIT loss. Cash consumption of US$214m over the past year also increases its risk profile.